A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…
Glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
Reyobiq (Rhenium Re186 Obisbemeda), an experimental radiation therapy being developed by Plus Therapeutics, has been cleared by the U.S. Food and Drug Administration (FDA)…
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.
